
Mexico Radiopharmaceuticals Market By Radioisotope (Technetium 99m, Fluorine 18, Iodine I, Gallium 68, Others), By Application (Cancer, Cardiology, Others), By Type (Diagnostic, Therapeutic), By End User (Hospitals and clinics, Medical Imaging centers, Ot
Description
Mexico Radiopharmaceuticals Market By Radioisotope (Technetium 99m, Fluorine 18, Iodine I, Gallium 68, Others), By Application (Cancer, Cardiology, Others), By Type (Diagnostic, Therapeutic), By End User (Hospitals and clinics, Medical Imaging centers, Others): Opportunity Analysis and Industry Forecast, 2023-2032
The Mexico radiopharmaceuticals market is expected to witness a favorable growth during the forecast period. With the rise in investments in R&D of radiopharmaceuticals for clinical and restorative applications, the market is expected to witness significant growth. The essential radioisotopes in the radiopharmaceuticals market in Mexico are Technetium 99m, Fluorine 18, Iodine I, Gallium 68, and also others. The significant applications of radiopharmaceuticals in Mexico include cancer, cardiology, and others. In terms of type, the major radiopharmaceuticals in the Mexican market are diagnostic and therapeutic. The major customers of radiopharmaceuticals are hospitals & clinics, medical imaging centers, and others.
The development of the Mexico radiopharmaceuticals market can be attributed to factors such as a rising prevalence of cancer worldwide, technical improvements in radiopharmaceuticals, as well as using radiopharmaceuticals for medical diagnosis of specific diseases. The rising prevalence of cancer cells in Mexico as well as the increasing demand for early diagnosis of cancer cells are anticipated to be the major factors driving the development in this market. The rising preference for nuclear medicine procedures owing to its effectiveness for imaging as well as medical diagnosis is additionally expected to drive the growth of the market. In addition, the introduction of 3D printing innovation in the production of radiopharmaceuticals is anticipated to develop opportunities for new product launches during the forecast years.
On the contrary, the rigid governing regulations as well as the high cost of radiopharmaceuticals are anticipated to act as restricting factors for the market growth. Furthermore, stringent federal government regulations regarding the supply and circulation are expected to hamper the development of the market during the forecast years.
The market environment of Mexico radiopharmaceuticals is studied by using Porter’s 5 forces analysis. Threat of new participants, negotiating power of purchasers, negotiating power of distributors, threat of substitutes, and degree of competitive rivalry in the market are taken into consideration. The risk of new entrants out there is mini due to stringent guidelines associated with the manufacturing and sale of radiopharmaceuticals. In addition, the presence of many well-known players in the market also restricts the entry of new players as well as creates a competitive environment in the market. The bargaining power of purchasers in the market is moderate owing to the presence of several well-known distributors. Moreover, the vendors usually offer discount rates to customers for bulk orders, which further strengthens their power in the market.
The bargaining power of distributors is low, owing to the visibility of presence distributors. In addition, customers can conveniently switch over to a different supplier owing to the presence of several providers in the market. The threat of alternatives is low, due to the benefits of radiopharmaceuticals for diagnosis and imaging. The accessibility of alternatives such as optical imaging and magnetic vibration imaging for imaging & medical diagnosis is low. The level of competitive rivalry in the market is high due to the existence of reputable players in the industry. In addition, the introduction of new modern technologies and the substantial financial investments in R&D tasks in the sector have actually increased the number of competitors in the market.
The future trends in the Mexico radiopharmaceuticals market include the introduction of new radiopharmaceuticals, R&D in the field of imaging, and the presence of new players in the market. The use of radiopharmaceuticals in targeted therapies is expected to increase in the upcoming years. In addition, the increasing awareness about the benefits of radiopharmaceuticals is anticipated to drive the growth of the market during the forecast period.
The demand need for radiopharmaceuticals from the healthcare facilities and clinical imaging facilities is expected to boost the market growth. Furthermore, the rising technical innovations in radiopharmaceuticals is expected to create possibilities for new product launches in the market. The leading players in the Mexico radiopharmaceuticals market are focusing on launching new products in the market. They are additionally investing dramatically in R&D tasks. For instance, in March 2019, the U.S.-based radioisotope business, PETnet Solutions, released a brand-new radioisotope, Technetium 99m, in Mexico. In addition, the business has actually established solution facilities in significant cities of Mexico, which offers radiopharmaceuticals to the local healthcare facilities.
The leading companies are also concentrating on expanding their manufacturing capacity. For instance, in February 2020, the Mexican radiopharmaceuticals firm, Ergomed, announced the development of its radiopharmaceuticals.
Key companies profile in the report are Sanofi, Gammaglobulin, Grupo Angel, Promecaps SA, Radiofarm SA de CV, Micro-Innova SA de CV, Nucleomex SA de CV, Plena Pharma SA de CV, Bioenex SA de CV, Farmefluar SA de CV.
The radiopharmaceuticals market share is segmented into Radioisotope, Application, Type, End User, and region. On the basis of radioisotopes, the market is classified into Technetium-99m, Fluorine-18, Iodine I, Gallium-68, and others. On the basis of application, the market is divided into cancer, cardiology, and others. On the basis of type, the market is bifurcated into diagnostic, and therapeutic. On the basis of end user, the market is fragmented into hospitals and clinics, medical imaging centers, and others. The others segment includes diagnostic centers, and research institute.
Key Benefits For Stakeholders
Enable informed decision-making process and offer market analysis based on current market situation and estimated future trends.
Analyze the key strategies adopted by major market players in mexico radiopharmaceuticals market.
Assess and rank the top factors that are expected to affect the growth of mexico radiopharmaceuticals market.
Top Player positioning provides a clear understanding of the present position of market players.
Detailed analysis of the mexico radiopharmaceuticals market segmentation assists to determine the prevailing market opportunities.
Identify key investment pockets for various offerings in the market.
New Product Development/ Product Matrix of Key Players
Patient/epidemiology data at country, region, global level
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
Key player details (including location, contact details, supplier/vendor network etc. in excel format)
SWOT Analysis
Key Market Segments
By Type
Diagnostic
Therapeutic
By End User
Hospitals and clinics
Medical Imaging centers
Others
By Radioisotope
Fluorine 18
Iodine I
Gallium 68
Others
Technetium 99m
By Application
Cancer
Cardiology
Others
Key Market Players
Sanofi
Gammaglobulin
Grupo Angel
Promecaps SA
Radiofarm SA de CV
Micro-Innova SA de CV
Nucleomex SA de CV
Plena Pharma SA de CV
Bioenex SA de CV
Farmefluar SA de CV
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
Table of Contents
78 Pages
- CHAPTER 1: INTRODUCTION
- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits to the Stakeholders
- 1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET OVERVIEW
- 3.1. Market Definition and Scope
- 3.2. Key Findings
- 3.2.1. Top Impacting Factors
- 3.2.2. Top Investment Pockets
- 3.3. Porter’s Five Forces Analysis
- 3.4. Market Dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities
- 3.5. COVID-19 Impact Analysis on the market
- CHAPTER 4: MEXICO RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE
- 4.1. Overview
- 4.1.1. Market Size and Forecast, By Radioisotope
- 4.2. Technetium 99m
- 4.3. Fluorine 18
- 4.4. Iodine I
- 4.5. Gallium 68
- 4.6. Others
- CHAPTER 5: MEXICO RADIOPHARMACEUTICALS MARKET, BY APPLICATION
- 5.1. Overview
- 5.1.1. Market Size and Forecast, By Application
- 5.2. Cancer
- 5.3. Cardiology
- 5.4. Others
- CHAPTER 6: MEXICO RADIOPHARMACEUTICALS MARKET, BY TYPE
- 6.1. Overview
- 6.1.1. Market Size and Forecast, By Type
- 6.2. Diagnostic
- 6.3. Therapeutic
- CHAPTER 7: MEXICO RADIOPHARMACEUTICALS MARKET, BY END USER
- 7.1. Overview
- 7.1.1. Market Size and Forecast, By End User
- 7.2. Hospitals and clinics
- 7.3. Medical Imaging centers
- 7.4. Others
- CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top player positioning, 2022
- CHAPTER 9: COMPANY PROFILES
- 9.1. Company 1
- 9.1.1. Company overview
- 9.1.2. Key Executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
- 9.2. Company 2
- 9.2.1. Company overview
- 9.2.2. Key Executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.2.7. Key strategic moves and developments
- 9.3. Company 3
- 9.3.1. Company overview
- 9.3.2. Key Executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.3.7. Key strategic moves and developments
- 9.4. Company 4
- 9.4.1. Company overview
- 9.4.2. Key Executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
- 9.4.7. Key strategic moves and developments
- 9.5. Company 5
- 9.5.1. Company overview
- 9.5.2. Key Executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
- 9.5.7. Key strategic moves and developments
- 9.6. Company 6
- 9.6.1. Company overview
- 9.6.2. Key Executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.6.7. Key strategic moves and developments
- 9.7. Company 7
- 9.7.1. Company overview
- 9.7.2. Key Executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.7.7. Key strategic moves and developments
- 9.8. Company 8
- 9.8.1. Company overview
- 9.8.2. Key Executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.8.7. Key strategic moves and developments
- 9.9. Company 9
- 9.9.1. Company overview
- 9.9.2. Key Executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
- 9.9.7. Key strategic moves and developments
- 9.10. Company 10
- 9.10.1. Company overview
- 9.10.2. Key Executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- 9.10.7. Key strategic moves and developments
- LIST OF TABLES
- TABLE 01. MEXICO RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
- TABLE 02. MEXICO RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 03. MEXICO RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 04. MEXICO RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 05. COMPANY 1: KEY EXECUTIVES
- TABLE 06. COMPANY 1: COMPANY SNAPSHOT
- TABLE 07. COMPANY 1: OPERATING SEGMENTS
- TABLE 08. COMPANY 1: PRODUCT PORTFOLIO
- TABLE 09. COMPANY 1: KEY STRATERGIES
- TABLE 10. COMPANY 2: KEY EXECUTIVES
- TABLE 11. COMPANY 2: COMPANY SNAPSHOT
- TABLE 12. COMPANY 2: OPERATING SEGMENTS
- TABLE 13. COMPANY 2: PRODUCT PORTFOLIO
- TABLE 14. COMPANY 2: KEY STRATERGIES
- TABLE 15. COMPANY 3: KEY EXECUTIVES
- TABLE 16. COMPANY 3: COMPANY SNAPSHOT
- TABLE 17. COMPANY 3: OPERATING SEGMENTS
- TABLE 18. COMPANY 3: PRODUCT PORTFOLIO
- TABLE 19. COMPANY 3: KEY STRATERGIES
- TABLE 20. COMPANY 4: KEY EXECUTIVES
- TABLE 21. COMPANY 4: COMPANY SNAPSHOT
- TABLE 22. COMPANY 4: OPERATING SEGMENTS
- TABLE 23. COMPANY 4: PRODUCT PORTFOLIO
- TABLE 24. COMPANY 4: KEY STRATERGIES
- TABLE 25. COMPANY 5: KEY EXECUTIVES
- TABLE 26. COMPANY 5: COMPANY SNAPSHOT
- TABLE 27. COMPANY 5: OPERATING SEGMENTS
- TABLE 28. COMPANY 5: PRODUCT PORTFOLIO
- TABLE 29. COMPANY 5: KEY STRATERGIES
- TABLE 30. COMPANY 6: KEY EXECUTIVES
- TABLE 31. COMPANY 6: COMPANY SNAPSHOT
- TABLE 32. COMPANY 6: OPERATING SEGMENTS
- TABLE 33. COMPANY 6: PRODUCT PORTFOLIO
- TABLE 34. COMPANY 6: KEY STRATERGIES
- TABLE 35. COMPANY 7: KEY EXECUTIVES
- TABLE 36. COMPANY 7: COMPANY SNAPSHOT
- TABLE 37. COMPANY 7: OPERATING SEGMENTS
- TABLE 38. COMPANY 7: PRODUCT PORTFOLIO
- TABLE 39. COMPANY 7: KEY STRATERGIES
- TABLE 40. COMPANY 8: KEY EXECUTIVES
- TABLE 41. COMPANY 8: COMPANY SNAPSHOT
- TABLE 42. COMPANY 8: OPERATING SEGMENTS
- TABLE 43. COMPANY 8: PRODUCT PORTFOLIO
- TABLE 44. COMPANY 8: KEY STRATERGIES
- TABLE 45. COMPANY 9: KEY EXECUTIVES
- TABLE 46. COMPANY 9: COMPANY SNAPSHOT
- TABLE 47. COMPANY 9: OPERATING SEGMENTS
- TABLE 48. COMPANY 9: PRODUCT PORTFOLIO
- TABLE 49. COMPANY 9: KEY STRATERGIES
- TABLE 50. COMPANY 10: KEY EXECUTIVES
- TABLE 51. COMPANY 10: COMPANY SNAPSHOT
- TABLE 52. COMPANY 10: OPERATING SEGMENTS
- TABLE 53. COMPANY 10: PRODUCT PORTFOLIO
- TABLE 54. COMPANY 10: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 01. MEXICO RADIOPHARMACEUTICALS MARKET, 2022-2032
- FIGURE 02. SEGMENTATION OF MEXICO RADIOPHARMACEUTICALS MARKET, 2022-2032
- FIGURE 03. TOP INVESTMENT POCKETS IN MEXICO RADIOPHARMACEUTICALS MARKET (2023-2032)
- FIGURE 04. PORTER FIVE-1
- FIGURE 05. PORTER FIVE-2
- FIGURE 06. PORTER FIVE-3
- FIGURE 07. PORTER FIVE-4
- FIGURE 08. PORTER FIVE-5
- FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: MEXICO RADIOPHARMACEUTICALS MARKET
- FIGURE 10. MEXICO RADIOPHARMACEUTICALS MARKET,BY RADIOISOTOPE, 2022 ($MILLION)
- FIGURE 11. MEXICO RADIOPHARMACEUTICALS MARKET,BY APPLICATION, 2022 ($MILLION)
- FIGURE 12. MEXICO RADIOPHARMACEUTICALS MARKET,BY TYPE, 2022 ($MILLION)
- FIGURE 13. MEXICO RADIOPHARMACEUTICALS MARKET,BY END USER, 2022 ($MILLION)
- FIGURE 14. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 15. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 16. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 17. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 18. COMPETITIVE DASHBOARD
- FIGURE 19. COMPETITIVE HEATMAP: MEXICO RADIOPHARMACEUTICALS MARKET
- FIGURE 20. TOP PLAYER POSITIONING, 2022
- FIGURE 21. COMPANY 1: NET SALES, 2020-2022* ($MILLION)
- FIGURE 22. COMPANY 1: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 23. COMPANY 1: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 24. COMPANY 2: NET SALES, 2020-2022* ($MILLION)
- FIGURE 25. COMPANY 2: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 26. COMPANY 2: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 27. COMPANY 3: NET SALES, 2020-2022* ($MILLION)
- FIGURE 28. COMPANY 3: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 29. COMPANY 3: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 30. COMPANY 4: NET SALES, 2020-2022* ($MILLION)
- FIGURE 31. COMPANY 4: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 32. COMPANY 4: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 33. COMPANY 5: NET SALES, 2020-2022* ($MILLION)
- FIGURE 34. COMPANY 5: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 35. COMPANY 5: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 36. COMPANY 6: NET SALES, 2020-2022* ($MILLION)
- FIGURE 37. COMPANY 6: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 38. COMPANY 6: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 39. COMPANY 7: NET SALES, 2020-2022* ($MILLION)
- FIGURE 40. COMPANY 7: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 41. COMPANY 7: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 42. COMPANY 8: NET SALES, 2020-2022* ($MILLION)
- FIGURE 43. COMPANY 8: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 44. COMPANY 8: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 45. COMPANY 9: NET SALES, 2020-2022* ($MILLION)
- FIGURE 46. COMPANY 9: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 47. COMPANY 9: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 48. COMPANY 10: NET SALES, 2020-2022* ($MILLION)
- FIGURE 49. COMPANY 10: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 50. COMPANY 10: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.